Latham & Watkins represented Ardelyx, Inc. in the transaction in the transaction. Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop...
Ardelyx’s $20 Million Agreement with HealthCare Royalty Partners
Rhythm Pharmaceuticals’ $100 Million Revenue Interest Financing Agreement With HealthCare Royalty Partners
Latham & Watkins represented Rhythm Pharmaceuticals, Inc. in the transaction, while Morgan, Lewis & Bockius acted as legal advisor to HealthCare Royalty. Rhythm Pharmaceuticals, Inc. (Nasdaq:...
Brilliant Earth’s $105 Million Financing
Latham & Watkins represented Brilliant Earth in the transaction. Brilliant Earth is a digitally native, omnichannel fine jewelry company and a global leader in ethically sourced fine...
ZenLedger’s $15 Million Series B Funding
Latham & Watkins advised ParaFi Capital in the transaction. ZenLedger, a global leader in cryptocurrency data analysis, accounting, and tax, announced the close of its US$15...
FirstClose’s $35 Million Funding Round
Latham & Watkins represented Lateral Investment Management on the transaction. FirstClose, a leading property and borrower data intelligence provider, has closed a US$35 million funding round...
Ouster’s $50 Million Structured Debt Facility
Latham & Watkins represented Ouster, Inc. on the deal. Ouster, Inc., a leading lidar technology developer, executed an up to US$50 million structured debt facility from Hercules...
BridgeBio Pharma’s Credit Facility Amendment
Latham & Watkins advised BridgeBio on the deal. BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, has entered into...
Alborz’s $46.9 Million Secured Credit Facility
Latham & Watkins advised Cipher Mining in the transaction. Alborz LLC, a joint venture affiliate of Cipher Mining Inc. (NASDAQ: CIFR) and WindHQ LLC, has announced...
Impulse Dynamics’ $101 Million Financing Round
Latham & Watkins represented Kennedy Lewis Investment Management LLC in the transaction. Impulse Dynamics, a global medical device company a medical device company organized in Curacao...
HilleVax’s $200 Million Initial Public Offering
Latham & Watkins represented HilleVax, while Davis Polk advised the joint book-running managers in the IPO. HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and...
Turn/River Capital’s $570 Million Acquisition of Tufin
Kirkland & Ellis advised Turn/River Capital, while White & Case and Meitar Law Office advised Tufin Software Technologies Ltd. on the deal. Latham & Watkins advised...
OXIO’s $40 Million Series B Funding
Latham & Watkins represented ParaFi Capital in the transaction. OXIO, the first telecom-as-a-service platform for brands and enterprises with a white-label, fully-customizable solution to help turn...